Aging bone and osteoporosis: strategies for preventing fractures in the elderly
- PMID: 14557222
- DOI: 10.1001/archinte.163.18.2237
Aging bone and osteoporosis: strategies for preventing fractures in the elderly
Abstract
As the older population increases, the incidence of osteoporotic fractures is expected to dramatically rise during the next few decades. Older patients are much more susceptible to fracture at any given bone mineral density (BMD) than are younger patients because of various factors, including the quality of aging bone, which involves more than BMD. Suppression of increased bone turnover by antiresorptive therapies, even with only small changes in BMD, can reduce fracture risk, especially in the lumbar spine. Bisphosphonate treatment can significantly reduce vertebral and nonvertebral fractures, including hip fractures, even in the very elderly. Prospective analyses show that risedronate therapy consistently and significantly reduces the risk of new morphometric vertebral fractures after 1 year in postmenopausal women. Post hoc analyses report significant reductions in the risk of 1 new clinical vertebral fracture after 6 months of risedronate therapy and after 1 year of alendronate therapy. Oral raloxifene therapy and salmon calcitonin nasal spray therapy have been shown to reduce the risk of vertebral fracture after 3 and 5 years, respectively, and post hoc data show a significant reduction in clinical vertebral fracture risk at 1 year with raloxifene use. However, neither raloxifene therapy nor calcitonin therapy reduce the risk of nonvertebral and hip fractures at currently approved doses. Bisphosphonates have been shown to be safe and efficacious with 7 years' risedronate sodium and 10 years' alendronate sodium data published, and bisphosphonates reduce bone turnover and increase BMD to a greater degree than raloxifene and calcitonin, which may partly account for their nonvertebral and hip fracture reduction effect. Therefore, bisphosphonate therapy with risedronate or alendronate should be considered in patients with low BMD at the hip and in older patients with osteoporosis and osteopenia, particularly those with an existing fracture.
Similar articles
-
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.Int J Clin Pharmacol Res. 2004;24(1):1-10. Int J Clin Pharmacol Res. 2004. PMID: 15575171
-
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.J Bone Miner Res. 2004 Feb;19(2):323-9. doi: 10.1359/JBMR.0301231. Epub 2003 Dec 16. J Bone Miner Res. 2004. PMID: 14969403 Clinical Trial.
-
Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.J Reprod Med. 2003 Jun;48(6):425-34. J Reprod Med. 2003. PMID: 12856513 Review.
-
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.Curr Med Res Opin. 2006 May;22(5):919-28. doi: 10.1185/030079906X100276. Curr Med Res Opin. 2006. PMID: 16709313 Review.
-
Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.Arch Intern Med. 1997 Dec 8-22;157(22):2617-24. Arch Intern Med. 1997. PMID: 9531231 Clinical Trial.
Cited by
-
Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study.Clin Cases Miner Bone Metab. 2013 Jan;10(1):56-60. doi: 10.11138/ccmbm/2013.10.1.056. Clin Cases Miner Bone Metab. 2013. PMID: 23858313 Free PMC article.
-
The Effect of Denosumab on Bone Mass in Super Elderly Patients.J Bone Metab. 2020 May;27(2):119-124. doi: 10.11005/jbm.2020.27.2.119. Epub 2020 May 31. J Bone Metab. 2020. PMID: 32572372 Free PMC article.
-
All-trans retinoic acid shifts rosiglitazone-induced adipogenic differentiation to osteogenic differentiation in mouse embryonic fibroblasts.Int J Mol Med. 2016 Dec;38(6):1693-1702. doi: 10.3892/ijmm.2016.2782. Epub 2016 Oct 19. Int J Mol Med. 2016. PMID: 27779644 Free PMC article.
-
Risk factors for new vertebral compression fracture after kyphoplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study.Medicine (Baltimore). 2022 Dec 9;101(49):e32018. doi: 10.1097/MD.0000000000032018. Medicine (Baltimore). 2022. PMID: 36626490 Free PMC article. Review.
-
Applications of a New Handheld Reference Point Indentation Instrument Measuring Bone Material Strength.J Med Device. 2013 Dec;7(4):410051-410056. doi: 10.1115/1.4024829. Epub 2013 Sep 24. J Med Device. 2013. PMID: 24115973 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials